The 12 closest competitors and alternatives to Delfi Diagnostics, Inc. among diagnostics companies — ranked by similarity to what Delfi Diagnostics, Inc. actually does, not by market-cap band.
Subscribe to see Delfi Diagnostics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
DELFI Diagnostics is a cancer detection company that utilizes artificial intelligence and whole genome fragmentation analysis to develop blood-based cancer screening tests, such as for lung cancer.
Delfi Diagnostics, Inc. is a diagnostics company headquartered in United States. It has raised at least $365.9M across the 5 funding rounds on record. Its most recent funding round raised $34.3M in December 2025. Xcout tracks 36 named people at Delfi Diagnostics, Inc., including Susan Tousi (Chief Executive Officer). Xcout recorded 14 job postings from Delfi Diagnostics, Inc. in the last 90 days, naming tools such as Palo Alto Networks.
30 more named people on record for Delfi Diagnostics, Inc., with roles, board committees and tenure — see the full roster →
At least $365.9M raised across the 5 rounds on record. The 4 most recent:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $34.3M | — | |
| Series B | $225M | 13 named | |
| — | $101.1M | 13 named | |
| SEC Form D filing | $5.5M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Xcout recorded 14 job postings from Delfi Diagnostics, Inc. in the last 90 days, from a hiring record Xcout has kept since July 2026.
The weekly hiring trend, the roles and locations behind it — see Delfi Diagnostics, Inc.'s hiring signals →
Ranked by semantic similarity — how close each company is to Delfi Diagnostics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
Identifai Genetics is a clinical-stage biotechnology and health tech company developing advanced prenatal screening tests using AI, machine learning, and whole genome analysis. It is headquartered in Rosh Haayin, Israel.
Biotechnology
PhiTech is a TechBio biotechnology company headquartered in Gebze, Kocaeli, Turkey. The firm leads a global shift from DNA-only diagnostics to AI-powered multi-omics, establishing new standards for precision medicine. Utilizing advanced bioinformatics and decision analysis, the company develops cutting-edge diagnostic tools.
Biotechnology
Durin Life Sciences develops Duritect™, a blood-based test that combines autoantibody biomarkers with machine learning technology to assess patients' risk of having Alzheimer's disease or Parkinson's disease. The company provides laboratory analysis services to process these blood samples and deliver risk score reports to physicians and patients.
Biotechnology
Day Zero Diagnostics, Inc. is a Boston-based company founded in 2016 that is pioneering a new class of infectious disease diagnostics using whole-genome sequencing and machine learning to address antibiotic resistance.
Healthcare
Inocras Inc. is a bioinformatics-led biotechnology company headquartered in San Diego, California. The firm utilizes whole genome data and proprietary artificial intelligence analytics to deliver curated genomic care.
Biotechnology
Nexosome Oncology Holdings, Inc. develops blood tests for early-stage cancer detection using patented extracellular vesicle proteomics and AI/ML biomarker discovery. The company serves patients and healthcare partners by providing highly accurate diagnostic tools.
Biotech
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's first commercial-stage test, SimpleScreen CRC for colorectal cancer, is under review by the U.S. Food and Drug Administration (FDA).
Medical Diagnostics, Biomedical Engineering, Liquid Biopsy
Nucleix is a liquid biopsy company headquartered in Rehovot, Israel. It aims to revolutionize cancer treatment through earlier disease detection, focusing on interventions that can bring the greatest impact.
Biotech
Gene Solutions LLC provides AI-powered genetic testing and multi-dimensional genomics services focused on oncology and reproductive health. The company offers blood-based early cancer detection tests, tumor profiling, and minimal residual disease monitoring for patients and healthcare providers.
Biotech
Precede Biosciences is a biotechnology company developing blood-based liquid-biopsy technologies for molecular profiling of cancer. Its tests are intended to support oncology research, precision treatment decisions, and pharmaceutical drug-development programs.
Biotechnology
Predicine Holdings Ltd provides next-generation liquid biopsy platforms and molecular profiling services for cancer research and precision medicine. The company utilizes proprietary blood- and urine-based assays to analyze circulating tumor DNA and RNA, serving biopharmaceutical partners and clinical researchers in oncology drug development and clinical trials.
Biotech
Belay Diagnostics is a medical and diagnostic laboratory based in Chicago, Illinois, that specializes in precision medicine and cerebrospinal fluid liquid biopsies for central nervous system cancers.
Search any company we track to see its competitive set.
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Delfi Diagnostics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →